FDA on Monday issued final guidelines that seek to limitation conflicts of interest among advisory committee members, the San Francisco Chronicle reports.
Under the guidelines, medical experts with more than a $50,000 financial pastime in companies cannot do on advisory committees that review their products or the products of their competitors. Medical experts with less than a $50,000 fiscal interest canful serve, provided that FDA considers their participation necessary and issues a discharge. The guidelines also permit FDA in certain cases to forbid participation on advisory committees by some medical experts, regardless of whether they have more than than a $50,000 financial interest group. The $50,000 limit includes stock, grants and other financial interests (Tansey, San Francisco Chronicle, 8/5).
In addition, FDA will change the balloting process for advisory committee members from sequential, which often can buoy influence the votes of other members, to concurrent. FDA testament post a record of the votes of individual advisory commission members on-line. FDA as well will post briefing materials online 48 hours earlier advisory citizens committee meetings and change the circumstances under which committees meet to address issues.
FDA officials said that the guidelines will subscribe effect directly and testament be fully implemented within 120 years (Parnass, CQ HealthBeat, 8/4).
Comments
Randall Lutter, a deputy FDA policy commissioner, said, "It's imperative mood that we seek advice from independent experts and that we do so in a way that is public, open and transparent" (Bloomberg/Boston Globe, 8/4). He aforementioned, "The FDA's regulatory decisions affect the health of millions of Americans, and we don't make those decisions in a vacuum" (CQ HealthBeat, 8/4). Jill Warner, senior policy adviser at FDA, said that agency efforts to discover medical experts without conflicts of pursuit have proved difficult. She said, "To develop innovational products, industry relies on the same experts."
Sidney Wolfe, managing director of the Health Research Group at Public Citizen, praised the guidelines. He said, "The whole underlying thought is that money talks," adding, "It is at least possible, though it's non certain, that it'll affect their voter turnout" (San Francisco Chronicle, 8/5). In addition, he aforesaid, "Over time, the part of people who hold these (conflicts) will decrease," adding, "A lot of it volition have to do with how much energy the FDA is willing to expend to find people who don't have a conflict of interest."
Diana Zuckerman, prexy of the National Research Center for Women & Families, aforesaid that FDA should come down the $50,000 demarcation and that she expects many medical experts with less than a $50,000 fiscal interest to receive waivers to attend to on advisory committees. She said, "The FDA has consistently used a identical low standard for granting waivers, and there is no evidence that this will change" (Freking, AP/Boston Globe, 8/4).
Reprinted with kind permission from http://www.kaisernetwork.org. You canful view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for e-mail delivery at http://www.kaisernetwork.
